Topical Botox developer Revance Therapeutics Inc. priced its initial public offering (IPO) at the top of the projected range, sold more shares than expected and came out of the gate strong, with the stock (NASDAQ:RVNC) closing Thursday at $26.85, up $10.85, or 67.8 percent.